Edition:
United States

Accuray Inc (ARAY.O)

ARAY.O on Nasdaq

4.15USD
26 May 2017
Change (% chg)

$0.15 (+3.75%)
Prev Close
$4.00
Open
$4.00
Day's High
$4.15
Day's Low
$3.95
Volume
508,347
Avg. Vol
835,088
52-wk High
$6.39
52-wk Low
$3.85

ARAY.O

Chart for ARAY.O

About

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife... (more)

Overall

Beta: 1.32
Market Cap(Mil.): $344.45
Shares Outstanding(Mil.): 83.00
Dividend: --
Yield (%): --

Financials

  ARAY.O Industry Sector
P/E (TTM): -- 44.95 17.41
EPS (TTM): -0.39 -- --
ROI: -16.55 8.89 -5.42
ROE: -58.50 13.82 -4.68

BRIEF-Accuray reports prelim data from phase I trial of breast cancer cure treated with Cyberknife System

* Prelim data from phase I trial evaluating adjuvant stereotactic partial breast irradiation in early stage breast cancer patients treated with Cyberknife System

May 02 2017

BRIEF-Accuray Q3 loss per share $0.06

* Accuray Inc - gross product orders totaled $83.8 million for 2017 fiscal Q3 compared to $56.4 million for prior fiscal year period

Apr 27 2017

BRIEF-Brian Grossman reports 5 pct passive stake in Accuray Inc as of March 6 - SEC filing

* Brian Grossman reports 5.0 percent passive stake in Accuray Inc as of March 6 - SEC filing Source text: (http://bit.ly/2neXxWb) Further company coverage:

Mar 16 2017

BRIEF-Accuray on March 10, co entered into an amendment to financing agreement dated as of Jan. 11, 2016

* On March 10, co entered into an amendment to financing agreement dated as of January 11, 2016 - sec filing

Mar 10 2017

BRIEF-Accuray posts Q2 loss per share $0.11

* Q2 ending product backlog was $426.2 million, approximately 16 percent higher

Jan 31 2017

More From Around the Web

Competitors

Earnings vs. Estimates